
Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies.




